Logotype for Green Thumb Industries Inc

Green Thumb Industries (GTII) Q1 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Green Thumb Industries Inc

Q1 2025 earnings summary

23 Apr, 2026

Executive summary

  • First quarter 2025 revenue reached $280 million, up 1.4% year-over-year, despite ongoing pricing pressures and macroeconomic uncertainty from tariffs and regulatory ambiguity.

  • Adjusted EBITDA was $85.2 million (30.5% of revenue), down from $90.5 million (32.8%) in the prior year, with cash flow from operations at $74 million, reflecting operational resilience.

  • Net income was $8.3 million ($0.04 per diluted share), down from $31.1 million ($0.13 per share) in the prior year, impacted by a prior year fair value adjustment.

  • The company maintains a strong balance sheet and is focused on long-term growth, capitalizing on shifting consumer trends favoring THC over alcohol.

  • Opened two new RISE Dispensaries in Nevada and Ohio, with grand opening profits donated to local charities.

Financial highlights

  • Revenue grew 1.4% year-over-year to $280 million, driven by a 14% increase in consumer packaged goods sales, while retail revenue declined due to pricing pressures.

  • Gross profit was $143.3 million (51.3% margin), down from $145 million (53% margin) last year, primarily due to price compression.

  • Retail revenue decreased 2.5% year-over-year, mainly from price compression in Illinois, Pennsylvania, New Jersey, and Connecticut, partially offset by growth in Ohio and New York.

  • Comparable store sales (stores open at least 12 months) declined 5.3% year-over-year on a base of 90 stores.

  • Total SG&A expenses were $100.8 million (36.1% of revenue), up from $74.3 million (26.9%) in Q1 2024, reflecting the absence of a prior year $15.9 million non-cash credit.

Outlook and guidance

  • Second quarter sequential revenue is expected to be flat due to continued pricing challenges.

  • Adjusted EBITDA margin is projected to fall below 30% in coming quarters as pricing pressures persist.

  • Capital expenditures for 2025 are expected to be approximately $80 million, in line with the prior year.

  • No expectation for sweeping federal cannabis reform in the near term; focus remains on operational efficiency and selective market investments.

  • Teams are preparing for the launch of adult-use sales in Minnesota, expected before year-end.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more